Inclusion Body Myositis

 

 Buy Article Permissions and Reprints

Abstract

The idiopathic inflammatory myopathies are a group of rare disorders that share many similarities. These include dermatomyositis (DM), polymyositis (PM), necrotizing myopathy (NM), and sporadic inclusion body myositis (IBM). Inclusion body myositis is the most common idiopathic inflammatory myopathy after age 50 and it presents with chronic proximal leg and distal arm asymmetric mucle weakness. Despite similarities with PM, it is likely that IBM is primarily a degenerative disorder rather than an inflammatory muscle disease. Inclusion body myositis is associated with a modest degree of creatine kinase (CK) elevation and an abnormal electromyogram demonstrating an irritative myopathy with some chronicity. The muscle histopathology demonstrates inflammatory exudates surrounding and invading nonnecrotic muscle fibers often times accompanied by rimmed vacuoles. In this chapter, we review sporadic IBM. We also examine past, essentially negative, clinical trials in IBM and review ongoing clinical trials. For further details on DM, PM, and NM, the reader is referred to the idiopathic inflammatory myopathies chapter.

• References

• 1 Phillips BA, Zilko PJ, Mastaglia FL. Prevalence of sporadic inclusion body myositis in Western Australia. Muscle Nerve 2000; 23 (6) 970-972
  CrossrefPubMedGoogle Scholar
• 2 Badrising UA, Maat-Schieman M, van Duinen SG , et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology 2000; 55 (9) 1385-1387
  CrossrefPubMedGoogle Scholar
• 3 Wilson FC, Ytterberg SR, St Sauver JL, Reed AM. Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota. J Rheumatol 2008; 35 (3) 445-447
  PubMedGoogle Scholar
• 4 Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008; 70 (6) 418-424
  CrossrefPubMedGoogle Scholar
• 5 Lotz BP, Engel AG, Nishino H, Stevens JC, Litchy WJ. Inclusion body myositis. Observations in 40 patients. Brain 1989; 112 (Pt 3) 727-747
  CrossrefPubMedGoogle Scholar
• 6 Badrising UA, Maat-Schieman ML, van Houwelingen JC , et al. Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients. J Neurol 2005; 252 (12) 1448-1454
  CrossrefPubMedGoogle Scholar
• 7 Lindberg C, Persson LI, Björkander J, Oldfors A. Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases. Acta Neurol Scand 1994; 89 (2) 123-131
  PubMedGoogle Scholar
• 8 Sayers ME, Chou SM, Calabrese LH. Inclusion body myositis: analysis of 32 cases. J Rheumatol 1992; 19 (9) 1385-1389
  PubMedGoogle Scholar
• 9 Amato AA, Gronseth GS, Jackson CE , et al. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol 1996; 40 (4) 581-586
  CrossrefPubMedGoogle Scholar
• 10 Barohn RJ, Amato AA. Inclusion body myositis. Curr Treat Options Neurol 2000; 2 (1) 7-12
  CrossrefPubMedGoogle Scholar
• 11 Needham M, James I, Corbett A , et al. Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases. J Neurol Neurosurg Psychiatry 2008; 79 (9) 1056-1060
  CrossrefPubMedGoogle Scholar
• 12 Larue S, Maisonobe T, Benveniste O , et al. Distal muscle involvement in granulomatous myositis can mimic inclusion body myositis. J Neurol Neurosurg Psychiatry 2011; 82 (6) 674-677
  CrossrefPubMedGoogle Scholar
• 13 Barohn RJ, Amato AA, Sahenk Z, Kissel JT, Mendell JR. Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology 1995; 45 (7) 1302-1304
  CrossrefPubMedGoogle Scholar
• 14 Hilton-Jones D, Miller A, Parton M, Holton J, Sewry C, Hanna MG. Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008. Neuromuscul Disord 2010; 20 (2) 142-147
  CrossrefPubMedGoogle Scholar
• 15 Griggs RC, Askanas V, DiMauro S , et al. Inclusion body myositis and myopathies. Ann Neurol 1995; 38 (5) 705-713
  CrossrefPubMedGoogle Scholar
• 16 Amato AA, Barohn RJ. Idiopathic inflammatory myopathies. Neurol Clin 1997; 15 (3) 615-648
  CrossrefPubMedGoogle Scholar
• 17 Garlepp MJ, Laing B, Zilko PJ, Ollier W, Mastaglia FL. HLA associations with inclusion body myositis. Clin Exp Immunol 1994; 98 (1) 40-45
  PubMedGoogle Scholar
• 18 Degardin A, Morillon D, Lacour A, Cotten A, Vermersch P, Stojkovic T. Morphologic imaging in muscular dystrophies and inflammatory myopathies. Skeletal Radiol 2010; 39 (12) 1219-1227
  CrossrefPubMedGoogle Scholar
• 19 Cox FM, Reijnierse M, van Rijswijk CS, Wintzen AR, Verschuuren JJ, Badrising UA. Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology (Oxford) 2011; 50 (6) 1153-1161
  CrossrefPubMedGoogle Scholar
• 20 Maetzler W, Reimold M, Schittenhelm J , et al. Increased [11C]PIB-PET levels in inclusion body myositis are indicative of amyloid beta deposition. J Neurol Neurosurg Psychiatry 2011; 82 (9) 1060-1062
  CrossrefPubMedGoogle Scholar
• 21 van der Meulen MF, Hoogendijk JE, Moons KG, Veldman H, Badrising UA, Wokke JH. Rimmed vacuoles and the added value of SMI-31 staining in diagnosing sporadic inclusion body myositis. Neuromuscul Disord 2001; 11 (5) 447-451
  CrossrefPubMedGoogle Scholar
• 22 Greenberg SA, Pinkus GS, Amato AA, Pinkus JL. Myeloid dendritic cells in inclusion-body myositis and polymyositis. Muscle Nerve 2007; 35 (1) 17-23
  CrossrefPubMedGoogle Scholar
• 23 Greenberg SA. Inclusion body myositis. Curr Opin Rheumatol 2011; 23 (6) 574-578
  CrossrefPubMedGoogle Scholar
• 24 Greenberg SA, Sanoudou D, Haslett JN , et al. Molecular profiles of inflammatory myopathies. Neurology 2002; 59 (8) 1170-1182
  CrossrefPubMedGoogle Scholar
• 25 Greenberg SA, Bradshaw EM, Pinkus JL , et al. Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 2005; 65 (11) 1782-1787
  CrossrefPubMedGoogle Scholar
• 26 Salajegheh M, Lam T, Greenberg SA. Autoantibodies against a 43 KDa muscle protein in inclusion body myositis. PLoS ONE 2011; 6 (5) e20266
  CrossrefPubMedGoogle Scholar
• 27 Askanas V, Engel WK. Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition. Neurology 2006; 66 (2) (Suppl. 01) S39-S48
  CrossrefPubMedGoogle Scholar
• 28 Askanas V, Engel WK. Sporadic inclusion-body myositis: conformational multifactorial ageing-related degenerative muscle disease associated with proteasomal and lysosomal inhibition, endoplasmic reticulum stress, and accumulation of amyloid-β42 oligomers and phosphorylated tau. Presse Med 2011; 40 (4 Pt 2) e219-e235
  CrossrefPubMedGoogle Scholar
• 29 Salajegheh M, Pinkus JL, Nazareno R, Amato AA, Parker KC, Greenberg SA. Nature of “Tau” immunoreactivity in normal myonuclei and inclusion body myositis. Muscle Nerve 2009; 40 (4) 520-528
  CrossrefPubMedGoogle Scholar
• 30 Nogalska A, D'Agostino C, Engel WK, Klein WL, Askanas V. Novel demonstration of amyloid-β oligomers in sporadic inclusion-body myositis muscle fibers. Acta Neuropathol 2010; 120 (5) 661-666
  CrossrefPubMedGoogle Scholar
• 31 Amato AA, Barohn RJ. Inclusion body myositis: old and new concepts. J Neurol Neurosurg Psychiatry 2009; 80 (11) 1186-1193
  CrossrefPubMedGoogle Scholar
• 32 Salajegheh M, Pinkus JL, Taylor JP , et al. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve 2009; 40 (1) 19-31
  CrossrefPubMedGoogle Scholar
• 33 Verma A, Bradley WG, Ringel SP. Treatment-responsive polymyositis transforming into inclusion body myositis. Neurology 2008; P060: 19
  PubMedGoogle Scholar
• 34 Benveniste O, Guiguet M, Freebody J , et al. Long-term observational study of sporadic inclusion body myositis. Brain 2011; 134 (Pt 11) 3176-3184
  CrossrefPubMedGoogle Scholar
• 35 Amato AA, Barohn RJ, Jackson CE, Pappert EJ, Sahenk Z, Kissel JT. Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology 1994; 44 (8) 1516-1518
  CrossrefPubMedGoogle Scholar
• 36 Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997; 48 (3) 712-716
  CrossrefPubMedGoogle Scholar
• 37 Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001; 56 (3) 323-327
  CrossrefPubMedGoogle Scholar
• 38 Muscle Study Group. Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis. Neurol (Tokyo) 2001; 57: 1566-1570
  CrossrefPubMedGoogle Scholar
• 39 Muscle Study Group. Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis. Neurol (Tokyo) 2004; 63: 718-720
  CrossrefPubMedGoogle Scholar
• 40 Badrising UA, Maat-Schieman ML, Ferrari MD , et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 2002; 51 (3) 369-372
  CrossrefPubMedGoogle Scholar
• 41 Lindberg C, Trysberg E, Tarkowski A, Oldfors A. Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology 2003; 61 (2) 260-262
  CrossrefPubMedGoogle Scholar
• 42 Rutkove SB, Parker RA, Nardin RA, Connolly CE, Felice KJ, Raynor EM. A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology 2002; 58 (7) 1081-1087
  CrossrefPubMedGoogle Scholar
• 43 Barohn RJ, Herbelin L, Kissel JT , et al. Pilot trial of etanercept in the treatment of inclusion-body myositis. Neurology 2006; 66 (2) (Suppl. 01) S123-S124
  CrossrefPubMedGoogle Scholar
• 44 Dalakas MC, Rakocevic G, Schmidt J , et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 2009; 132 (Pt 6) 1536-1544
  CrossrefPubMedGoogle Scholar
• 45 Sancricca C, Mora M, Ricci E, Tonali PA, Mantegazza R, Mirabella M. Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis. Neurol Sci 2011; 32 (5) 841-847
  CrossrefPubMedGoogle Scholar
• 46 Cox FM, Titulaer MJ, Sont JK, Wintzen AR, Verschuuren JJ, Badrising UA. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain 2011; 134 (Pt 11) 3167-3175
  CrossrefPubMedGoogle Scholar
• 47 Sekul EA, Dalakas MC. Inclusion body myositis: new concepts. Semin Neurol 1993; 13 (3) 256-263
  Article in Thieme ConnectPubMedGoogle Scholar
• 48 Arnardottir S, Alexanderson H, Lundberg IE, Borg K. Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction. J Rehabil Med 2003; 35 (1) 31-35
  CrossrefPubMedGoogle Scholar
• 49 Johnson GL , et al. The effectiveness of an individualized, home-based functional exercise program for patients with sporadic inclusion body myositis. J Clin Neuromuscul Dis 2007; 8: 187-194
  CrossrefPubMedGoogle Scholar
• 50 Johnson LG, Collier KE, Edwards DJ , et al. Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis. J Clin Neuromuscul Dis 2009; 10 (4) 178-184
  CrossrefPubMedGoogle Scholar
• 51 Takarada Y, Takazawa H, Sato Y, Takebayashi S, Tanaka Y, Ishii N. Effects of resistance exercise combined with moderate vascular occlusion on muscular function in humans. J Appl Physiol 2000; 88 (6) 2097-2106
  CrossrefPubMedGoogle Scholar
• 52 Wernbom M, Augustsson J, Raastad T. Ischemic strength training: a low-load alternative to heavy resistance exercise?. Scand J Med Sci Sports 2008; 18 (4) 401-416
  CrossrefPubMedGoogle Scholar
• 53 Gualano B, Neves Jr M, Lima FR , et al. Resistance training with vascular occlusion in inclusion body myositis: a case study. Med Sci Sports Exerc 2010; 42 (2) 250-254
  PubMedGoogle Scholar